专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2007149566A2 VIRAL SEQUENCES AND USES THEREOF 审中-公开
标题翻译：病毒序列及其用途
公开(公告)号：WO2007149566A2
公开(公告)日：2007-12-27
申请号：PCT/US2007014593
申请日：2007-06-21
申请人： VIRON THERAPEUTICS INC , MCFADDEN GRANT D , LUCAS ALEXANDRA , BARRET JOHN W
发明人： MCFADDEN GRANT D , LUCAS ALEXANDRA , BARRET JOHN W
IPC分类号： A61K39/12
CPC分类号： A61K48/00 , A61K38/162 , C07K14/005 , C07K2319/02 , C07K2319/21 , C07K2319/41 , C12N2710/24022
摘要： The invention features polypeptide and polynucleotide sequences based on the 134R sequence. In some embodiments, these sequences include a heterologous signal sequence, such as the myxoma virus T7 signal sequence. The invention also features methods- for treating immunological disorders and neoplasms (e.g., cancer) using the polypeptides and nucleotides described herein. Finally, the invention features fusion proteins including the myxoma virus T7 signal sequence.
摘要翻译：本发明的特征在于基于134R序列的多肽和多核苷酸序列。在一些实施方案中，这些序列包括异源信号序列，例如粘液瘤病毒T7信号序列。本发明还特征在于使用本文所述的多肽和核苷酸治疗免疫疾病和赘生物（例如癌症）的方法。最后，本发明的特征是融合蛋白包括粘液瘤病毒T7信号序列。

2. 发明申请

WO9744054A3 TYPE-2 CHEMOKINE BINDING PROTEINS AND METHODS OF USE THEREFOR 审中-公开
标题翻译： TYPE-2 CHEMOKINE BINDING蛋白及其使用方法
公开(公告)号：WO9744054A3
公开(公告)日：1998-05-14
申请号：PCT/US9708590
申请日：1997-05-21
申请人： UNIV ALBERTA , MCFADDEN GRANT , LUCAS ALEXANDRA
发明人： MCFADDEN GRANT , LUCAS ALEXANDRA
IPC分类号： A61K38/00 , A61K31/00 , A61K38/16 , A61K45/00 , A61P9/00 , A61P9/10 , A61P11/00 , A61P11/06 , A61P31/00 , A61P31/04 , A61P35/00 , A61P37/00 , C07K14/065 , G01N33/53 , G01N33/566
CPC分类号： C07K14/005 , A61K38/162 , C12N2710/24122
摘要： The present invention provides a method of use for a novel chemokine binding protein (type-2 CBP) encoded by poxviruses and having amino acid sequence homology with the Shope fibroma virus T1 family of proteins against disease syndromes associated with acute or chronic dysregulated inflammatory responses.

3. 发明申请

WO2007143538A3 PIKE-A ENHANCES INFECTION BY MYXOMA VIRUS 审中-公开
标题翻译： PIKE-A通过MYXOMA病毒增强感染
公开(公告)号：WO2007143538A3
公开(公告)日：2008-02-21
申请号：PCT/US2007070199
申请日：2007-06-01
申请人： ROBARTS RES INST , MCFADDEN GRANT , WERDEN STEVEN
发明人： MCFADDEN GRANT , WERDEN STEVEN
IPC分类号： C12N15/00
CPC分类号： A61K35/76 , A61K38/46 , C12Y306/05 , A61K2300/00
摘要： Cellular Akt activation is increased by transducing an Akt-containing cell with a vector that expresses exogenous PIKE-A (PIl 3 -kinase enhancer activating Akt) in the cell. Expression of PIKE-A increases the susceptibility of cancer cells to myxoma virus infection. Cancer is treated by administering a vector that infects cancer cells and expresses exogenous PIKE-A; and a myxoma virus. Cancer is treated by taking cancer cells from a subject, transducing them ex vivo with a vector that expresses exogenous PIKE-A in the cells, treating the transduced cells with a myxoma virus, and then returning the transduced cells to the subject. Alternatively, myxoma virus can be administered to the patient after the transduced cells have been returned to the patient. The susceptibility of cells to infection with a myxoma virus can be determined by assaying for PIKE-A expression. Cellular expression of PIKE-A in the cell indicates susceptibility to myxoma virus infection.
摘要翻译：通过用表达外源PIKE-A（PI3-3激酶增强子激活Akt）的载体转导含Akt的细胞来增加细胞Akt活化。 PIKE-A的表达增加了癌细胞对粘液瘤病毒感染的敏感性。通过施用感染癌细胞并表达外源性PIKE-A的载体来治疗癌症; 和粘液瘤病毒。通过从受试者中摄取癌细胞来治疗癌症，用在细胞中表达外源性PIKE-A的载体离体转染它们，用粘液瘤病毒处理转导的细胞，然后将转导的细胞返回到受试者。或者，在转导的细胞已经返回到患者之后，可以向患者施用粘液瘤病毒。可以通过测定PIKE-A表达来确定细胞对粘液瘤病毒感染的易感性。细胞中PIKE-A的细胞表达表明对粘液瘤病毒感染的敏感性。

4. 发明申请

WO2007149566A3 VIRAL SEQUENCES AND USES THEREOF 审中-公开
公开(公告)号：WO2007149566A3
公开(公告)日：2007-12-27
申请号：PCT/US2007/014593
申请日：2007-06-21
申请人： VIRON THERAPEUTICS INCORPORATED , MCFADDEN, Grant, D. , LUCAS, Alexandra , BARRET, John, W.
发明人： MCFADDEN, Grant, D. , LUCAS, Alexandra , BARRET, John, W.
IPC分类号： A61K39/00 , A61K39/12 , A61K39/125 , A61K39/155
摘要： The invention features polypeptide and polynucleotide sequences based on the 134R sequence. In some embodiments, these sequences include a heterologous signal sequence, such as the myxoma virus T7 signal sequence. The invention also features methods- for treating immunological disorders and neoplasms (e.g., cancer) using the polypeptides and nucleotides described herein. Finally, the invention features fusion proteins including the myxoma virus T7 signal sequence.

5. 发明申请

WO2007143545A2 TNF SIGNALING IN MYXOMA VIRUS TREATMENTS 审中-公开
标题翻译： TNF信号在MYXOMA病毒治疗中的作用
公开(公告)号：WO2007143545A2
公开(公告)日：2007-12-13
申请号：PCT/US2007070216
申请日：2007-06-01
申请人： ROBARTS RES INST , WELLSTAT BIOLOGICS CORP , MCFADDEN GRANT , WANG FUAN , ROBERTS MICHAEL SCOT
发明人： MCFADDEN GRANT , WANG FUAN , ROBERTS MICHAEL SCOT
IPC分类号： C12Q1/70
CPC分类号： C12Q1/6883
摘要： Cells that are deficient in TNF responsiveness are susceptible to infection with a myxoma virus. People infected with myxoma virus infection are treated using an activator of tumor necrosis factor receptor. MT-2 deficient myxoma viruses are useful in treating cancer.
摘要翻译：缺乏TNF反应性的细胞易感染粘液瘤病毒。感染粘液瘤病毒感染的人群使用肿瘤坏死因子受体激活剂治疗。 MT-2缺陷型粘液瘤病毒可用于治疗癌症。

6. 发明申请

WO2004106370A1 M11L DERIVED PEPTIDES AND THERAPEUTIC USE THEREOF 审中-公开
标题翻译： M11L衍生的肽及其治疗用途
公开(公告)号：WO2004106370A1
公开(公告)日：2004-12-09
申请号：PCT/EP2004/006581
申请日：2004-05-28
申请人： THERAPTOSIS SA , ROBARTS RESEARCH INSTITUTE , JACOTOT, Etienne , MCFADDEN, Grant
发明人： JACOTOT, Etienne , MCFADDEN, Grant
IPC分类号： C07K14/47
CPC分类号： C07K14/005 , A61K38/00 , C07K2319/00 , C12N2710/24022
摘要： This invention relates to a novel chimeric peptide derived from M11L protein of myxoma poxvirus capable of inhibiting apoptosis and its use as a cytoprotective molecule, as well as to pharmaceutical compositions containing the M11L derived chimeric peptides. Also provided are nucleic acid molecules that encode the chimeric anti-apoptotic peptides, and methods for using the proteins and nucleic acid molecules as cytoprotective molecules. The present invention further relates to a M11L fusion peptide possessing an uptake action and/or a targeted moiety into and to a cell and its use as apoptosis inhibitor. The M11L derived peptides and fusions peptides are useful for treating AIDS, neurodegenerative diseases, osteomyelodysplasia, ischemic diseases, infectious multiple organ failure, hepatitis, ischemic reperfusion disorders, diabetes and the like.
摘要翻译：本发明涉及能够抑制凋亡的粘液瘤痘病毒的M11L蛋白的新型嵌合肽及其作为细胞保护分子的用途，以及含有M11L衍生的嵌合肽的药物组合物。还提供编码嵌合抗凋亡肽的核酸分子，以及使用蛋白质和核酸分子作为细胞保护分子的方法。本发明还涉及具有吸收作用和/或靶向部分进入细胞和细胞的M11L融合肽及其作为细胞凋亡抑制剂的用途。 M11L衍生肽和融合肽可用于治疗AIDS，神经变性疾病，骨髓发育不良，缺血性疾病，感染性多器官功能衰竭，肝炎，缺血再灌注障碍，糖尿病等。

7. 发明申请

WO2004078206A1 USE OF MYXOMA VIRUS FOR THE THERAPEUTIC TREATMENT OF CANCER AND CHRONIC VIRAL INFECTION 审中-公开
标题翻译：用于治疗癌症和慢性病毒感染的MYXOMA病毒的使用
公开(公告)号：WO2004078206A1
公开(公告)日：2004-09-16
申请号：PCT/CA2004/000341
申请日：2004-03-08
申请人： ROBARTS RESEARCH INSTITUTE , MCFADDEN, Grant , BELL, John, C.
发明人： MCFADDEN, Grant , BELL, John, C.
IPC分类号： A61K39/275
CPC分类号： A61K35/768 , C12N2710/24032
摘要： The present invention relates to therapeutic use of Myxoma virus. Myxomas virus can selectively infect cells that have a deficient innate anti-viral response, including cells that are not responsive to interferon and can be used to treat diseases characterized by the presence of such cells, including cancer.
摘要翻译：本发明涉及粘液瘤病毒的治疗用途。粘液瘤病毒可以选择性感染具有缺陷先天性抗病毒应答的细胞，包括对干扰素无反应的细胞，可用于治疗特征在于存在这种细胞（包括癌症）的疾病。

8. 发明申请

WO2004039391A1 VIRAL SERPIN REGULATION OF INFLAMATION 审中-公开
标题翻译： VIRAL SERPIN调节爆发
公开(公告)号：WO2004039391A1
公开(公告)日：2004-05-13
申请号：PCT/CA2003/001682
申请日：2003-10-31
申请人： LUCAS, Alexandra, R. , MCFADDEN, Grant, D.
发明人： LUCAS, Alexandra, R. , MCFADDEN, Grant, D.
IPC分类号： A61K38/03
CPC分类号： A61K38/55
摘要： The present invention provides for a pharmaceutical composition containing at least one compound that promotes intracellular signalling via the human urokinase plasminogen activator receptor. The compound binds the human urokinase plasminogen activator receptor, the compound binds one or more intracellular protein(s) directly or indirectly associated with intracellular signalling via human urokinase plasminogen activator receptor, and the compound binds one or more intracellular protein(s) that are modulated by urokinase plasminogen activator receptor activity. The compound is an organic or inorganic compound with a molecular weight less than 1kDa, compound is a peptide between 2 and 20 amino acids in length, and the compound is a polypeptide greater than 20 amino acids in length. The compound is an antibody or fragment thereof, the compound is a nucleic acid, and the compound is administered to humans in vivo , and to human cells ex vivo . The composition includes a pharmaceutically acceptable carrier, and the composition is administered to a human individual for the treatment of an inflamatory condition.
摘要翻译：本发明提供含有至少一种通过人尿激酶纤溶酶原激活物受体促进细胞内信号传导的化合物的药物组合物。该化合物结合人尿激酶纤溶酶原激活物受体，该化合物通过人尿激酶纤溶酶原激活物受体直接或间接地与细胞内信号传导相关联的一种或多种细胞内蛋白质，并且该化合物结合调节的一种或多种细胞内蛋白质通过尿激酶纤溶酶原激活物受体活性。该化合物是分子量小于1kDa的有机或无机化合物，化合物是长度在2至20个氨基酸之间的肽，并且化合物是长度大于20个氨基酸的多肽。化合物是抗体或其片段，化合物是核酸，并且化合物在体内施用于人体，并且离体施用于人类细胞。组合物包括药学上可接受的载体，并且将组合物施用于人个体以治疗炎症状况。

9. 发明申请

WO2007147118A1 INFECTION OF CELLS WITH MYXOMA VIRUS REQUIRES AKT ACTIVATION 审中-公开
标题翻译：感染细胞与MYXOMA病毒需要AKT激活
公开(公告)号：WO2007147118A1
公开(公告)日：2007-12-21
申请号：PCT/US2007/071349
申请日：2007-06-15
申请人： ROBARTS RESEARCH INSTITUTE , BARRETT, John, W. , MCFADDEN, Grant
发明人： BARRETT, John, W. , MCFADDEN, Grant
IPC分类号： A61K39/12 , A01N63/00
CPC分类号： A61K38/45 , A61K35/768 , A61K2300/00
摘要： Decribed herein is a method of screening for, or increasing, the permissiveness of cells to oncolytic therapy with myxoma virus. This disclosure further describes the relationship between the activation state of Akt and relative permissiveness of cancer cells to myxoma virus infection and replication. Cellular Akt activation is increased by contacting Akt- containing cells with a medicament that increases endogenous Akt activation or transducing Akt-containing cells with a vector that expresses exogenous Akt in the cells. Cancer is treated by increasing Akt activation in cancer cells and administering a myxoma virus.
摘要翻译：本文所述的是筛选或增加细胞对粘液瘤治疗粘液瘤病毒的允许性的方法。本公开进一步描述了Akt的激活状态和癌细胞对粘液瘤病毒感染和复制的相对允许性之间的关系。通过使含Akt的细胞与增加内源Akt活化或用表达外源Akt的细胞转导含Akt的细胞的药物接触来增加细胞Akt活化。通过增加癌细胞中的Akt活化和施用粘液瘤病毒来治疗癌症。

10. 发明申请

WO2007143545A3 TNF SIGNALING IN MYXOMA VIRUS TREATMENTS 审中-公开
公开(公告)号：WO2007143545A3
公开(公告)日：2007-12-13
申请号：PCT/US2007/070216
申请日：2007-06-01
申请人： ROBARTS RESEARCH INSTITUTE , WELLSTAT BIOLOGICS CORPORATION , MCFADDEN, Grant , WANG, Fuan , ROBERTS, Michael, Scot
发明人： MCFADDEN, Grant , WANG, Fuan , ROBERTS, Michael, Scot
IPC分类号： C12Q1/70 , C12N7/00 , C12N15/00
摘要： Cells that are deficient in TNF responsiveness are susceptible to infection with a myxoma virus. People infected with myxoma virus infection are treated using an activator of tumor necrosis factor receptor. MT-2 deficient myxoma viruses are useful in treating cancer.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式